Authors

• Rupa Banerjee (ORCID: https://orcid.org/0000-0002-3753-4933)
• John Woolcott (ORCID: https://orcid.org/0000-0001-7445-8696)
• Tanja Kuehbacher
• Krisztina Lazin
• Michael J. Keating (ORCID: https://orcid.org/0000-0002-9121-6450)
• Gary R. Lichtenstein (ORCID: https://orcid.org/0000-0003-0815-2044)
• Silvio Danese (ORCID: https://orcid.org/0000-0001-7341-1351)
• Edward V. Loftus (ORCID: https://orcid.org/0000-0001-7199-6851)
• Peter M. Irving
• Aline Charabaty (ORCID: https://orcid.org/0000-0001-9810-3662)
• Jessica Ravikoff Allegretti (ORCID: https://orcid.org/0000-0003-3585-2425)
• Eustratios Bananis
• Alexis B Dalam
• Aoibhinn McDonnell (ORCID: https://orcid.org/0000-0002-2229-0382)

Institutions

• Brigham and Women's Hospital (US)
• Johns Hopkins University (US)
• Vita-Salute San Raffaele University (IT)
• Pfizer (United States) (US)
• Pfizer (United Kingdom) (GB)
• Guy's and St Thomas' NHS Foundation Trust (GB)
• Johns Hopkins Medicine (US)
• St. Marien- und St. Annastiftskrankenhaus (DE)
• Pfizer (Switzerland) (CH)
• Mayo Clinic in Arizona (US)
• Asian Institute of Gastroenterology (IN)
• University of Pennsylvania (US)

Publication Details

Journal

Inflammatory Bowel Diseases

Published

2025-04-04

DOI

https://doi.org/10.1093/ibd/izae308

Citations

4

Primary Topic

Inflammatory Bowel Disease

Type

article

Field-Weighted Citation Impact

7.27

Funders

• Pfizer